An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
S Al-Harbi, M Aljurf, M Mohty, F Almohareb… - Blood …, 2020 - ashpublications.org
Acute myeloid leukemia (AML) with t (8; 21)(q22; q22. 1); RUNX1-RUNX1T1, one of the core-
binding factor leukemias, is one of the most common subtypes of AML with recurrent genetic …
binding factor leukemias, is one of the most common subtypes of AML with recurrent genetic …
Clinical implications of inflammation in acute myeloid leukemia
C Récher - Frontiers in Oncology, 2021 - frontiersin.org
Recent advances in the description of the tumor microenvironment of acute myeloid
leukemia, including the comprehensive analysis of the leukemic stem cell niche and clonal …
leukemia, including the comprehensive analysis of the leukemic stem cell niche and clonal …
Depletion of RUNX1/ETO in t (8; 21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding
A Ptasinska, SA Assi, D Mannari, SR James… - Leukemia, 2012 - nature.com
Abstract The t (8; 21) translocation fuses the DNA-binding domain of the hematopoietic
master regulator RUNX1 to the ETO protein. The resultant RUNX1/ETO fusion protein is a …
master regulator RUNX1 to the ETO protein. The resultant RUNX1/ETO fusion protein is a …
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer
G Roti, A Carlton, KN Ross, M Markstein, K Pajcini… - Cancer cell, 2013 - cell.com
Notch1 is a rational therapeutic target in several human cancers, but as a transcriptional
regulator, it poses a drug discovery challenge. To identify Notch1 modulators, we performed …
regulator, it poses a drug discovery challenge. To identify Notch1 modulators, we performed …
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
MA Hatlen, L Wang, SD Nimer - Frontiers of medicine, 2012 - Springer
The AML1-ETO fusion transcription factor is generated by the t (8; 21) translocation, which is
present in approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid …
present in approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid …
Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery
The advent of powerful genomics technologies has uncovered many fundamental aspects of
biology, including the mechanisms of cancer; however, it has not been appropriately …
biology, including the mechanisms of cancer; however, it has not been appropriately …
TAF1 plays a critical role in AML1-ETO driven leukemogenesis
Y Xu, N Man, D Karl, C Martinez, F Liu, J Sun… - Nature …, 2019 - nature.com
Abstract AML1-ETO (AE) is a fusion transcription factor, generated by the t (8; 21)
translocation, that functions as a leukemia promoting oncogene. Here, we demonstrate that …
translocation, that functions as a leukemia promoting oncogene. Here, we demonstrate that …
Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity
L Simon, VP Lavallée, ME Bordeleau, J Krosl… - Clinical cancer …, 2017 - AACR
Abstract Purpose: RUNX1-mutated (RUNX1 mut) acute myeloid leukemia (AML) is
associated with adverse outcome, highlighting the urgent need for a better genetic …
associated with adverse outcome, highlighting the urgent need for a better genetic …
[HTML][HTML] Therapeutic targeting of notch signaling pathway in hematological malignancies
C Sorrentino, A Cuneo, G Roti - Mediterranean journal of …, 2019 - ncbi.nlm.nih.gov
The Notch pathway plays a key role in several processes, including stem-cell self-renewal,
proliferation, and cell differentiation. Several studies identified recurrent mutations in …
proliferation, and cell differentiation. Several studies identified recurrent mutations in …
Gene expression profiling in MDS and AML: potential and future avenues
K Theilgaard-Moench, J Boultwood, S Ferrari… - Leukemia, 2011 - nature.com
Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an …
leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an …